Medicinsk behandling af osteoporose hos mænd

Pia A Eiken; Peter Vestergaard

Medicinsk behandling af osteoporose hos mænd

Translated title of the contribution: Medical treatment of osteoporosis in men

Pia A Eiken, Peter Vestergaard

Abstract

One in five men over the age of 50 years will suffer an osteoporotic fracture during their lifetime, and men who sustain fractures have an increased mortality risk compared to women. Three bisphosphonates (alendronate, risedronate and zolendronic acid), denosumab, strontium ranelate and teriparatide are currently approved in Denmark for the treatment of osteoporosis in men. This review summarizes the available therapeutic options.

Translated title of the contribution	Medical treatment of osteoporosis in men
Original language	Danish
Article number	V03150220
Journal	Ugeskrift for Laeger
Volume	178
Issue number	6
Pages (from-to)	549-555
ISSN	0041-5782
Publication status	Published - 2016

Cite this

@article{c97e906ffa6445fd8eb7f8449467c7e1,

title = "Medicinsk behandling af osteoporose hos m{\ae}nd",

abstract = "One in five men over the age of 50 years will suffer an osteoporotic fracture during their lifetime, and men who sustain fractures have an increased mortality risk compared to women. Three bisphosphonates (alendronate, risedronate and zolendronic acid), denosumab, strontium ranelate and teriparatide are currently approved in Denmark for the treatment of osteoporosis in men. This review summarizes the available therapeutic options.",

author = "Eiken, \{Pia A\} and Peter Vestergaard",

year = "2016",

language = "Dansk",

volume = "178",

pages = "549--555",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "6",

}

TY - JOUR

T1 - Medicinsk behandling af osteoporose hos mænd

AU - Eiken, Pia A

AU - Vestergaard, Peter

PY - 2016

Y1 - 2016

N2 - One in five men over the age of 50 years will suffer an osteoporotic fracture during their lifetime, and men who sustain fractures have an increased mortality risk compared to women. Three bisphosphonates (alendronate, risedronate and zolendronic acid), denosumab, strontium ranelate and teriparatide are currently approved in Denmark for the treatment of osteoporosis in men. This review summarizes the available therapeutic options.

AB - One in five men over the age of 50 years will suffer an osteoporotic fracture during their lifetime, and men who sustain fractures have an increased mortality risk compared to women. Three bisphosphonates (alendronate, risedronate and zolendronic acid), denosumab, strontium ranelate and teriparatide are currently approved in Denmark for the treatment of osteoporosis in men. This review summarizes the available therapeutic options.

UR - https://www.scopus.com/pages/publications/85037700075

M3 - Tidsskriftartikel

C2 - 26324291

SN - 0041-5782

VL - 178

SP - 549

EP - 555

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 6

M1 - V03150220

ER -

Medicinsk behandling af osteoporose hos mænd

Abstract

Other files and links

Fingerprint

Cite this